Loading…
Suven Life Sciences (SUVEN)₹279.95+2.06%Healthcare Research, Analytics & Technology
At the end of the Sep 2026 quarter, Suven Life Sciences' shareholders were: promoters 65.41%, FIIs 0.48%, DIIs 2.75%, public 31.36%. Promoter holding is down 4.61 percentage points from 70.02% a quarter earlier. FII holding is down 0.70 percentage points from 1.18% a year earlier. 0.00% of promoter shares were pledged. It had 66,648 shareholders.
As of · Company filings (shareholding pattern)
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 69.50% | 69.50% | 70.20% | 70.20% | 70.20% | 70.20% | 70.20% | 67.30% | 67.30% | 70.09% | 70.02% | 65.41% |
| FIIs | 0.54% | 0.46% | 0.45% | 0.33% | 0.34% | 0.25% | 0.58% | 1.18% | 1.08% | 0.91% | 0.56% | 0.48% |
| DIIs | 0.01% | 1.06% | 1.06% | 1.06% | 1.06% | 0.01% | 0.03% | 3.41% | 3.41% | 4.65% | 2.95% | 2.75% |
| Public | 29.95% | 28.98% | 28.29% | 28.41% | 28.40% | 29.54% | 29.19% | 28.11% | 28.21% | 24.35% | 26.47% | 31.36% |
| Promoter shares pledged | — | — | — | — | — | — | — | — | — | — | — | 0.00% |
| Number of shareholders | 74,004 | 68,960 | 66,117 | 63,976 | 63,538 | 64,604 | 66,160 | 64,922 | 64,382 | 63,916 | 66,792 | 66,648 |
| Holder | Category | Sep 2026 | Change (pp) |
|---|---|---|---|
| JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED (In its Capacity as sole trustee of Jasti Family Trust) | Promoter | 64.88% | −4.57 |
| 3P India Equity Fund 1 | DII | 1.18% | −0.08 |
| Abakkus Diversified Alpha Fund | DII | 1.01% | −0.07 |
| Sudharani Jasti | Promoter | 0.54% | −0.04 |
Promoters held 65.41% of Suven Life Sciences at the end of the Sep 2026 quarter, down 1.89 percentage points from 67.30% a year earlier.
In the Sep 2026 quarter, foreign institutional investors (FIIs) held 0.48% (down 0.08 percentage points from 0.56% a quarter earlier) and domestic institutions (DIIs) held 2.75% (down 0.20 percentage points from 2.95% a quarter earlier).
No. The Sep 2026 filing shows no pledged promoter shares.
Suven Life Sciences had 66,648 shareholders at the end of the Sep 2026 quarter, against 64,922 a year earlier.
3P India Equity Fund 1 (DII) held 1.18% at the end of the Sep 2026 quarter, the largest named holding outside the promoter group.